Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bone Marrow Transplant with Busulfan/Cyclophosphamide and Post-Transplant Cyclophosphamide for Hematological Malignancies
NCT00134017Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jun 2004
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in hematologic malignancy, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Percentage of Participants Who Develop Acute Graft-versus-host Disease (GVHD) at Day 100. Started Jun 2004; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT00134017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00134017.